Caenorhabditis elegans as an emerging high throughput chronotherapeutic drug screening platform for human neurodegenerative disorders
Advanced Drug Delivery Reviews · 2025
DOI: 10.1016/j.addr.2025.115655 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2025. Verfasst von Mrutyunjaya Panda und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion 70013 Crete, Greece; Department of Medicin…. Hauptthemen laut MEDLINE: Caenorhabditis elegans, Neurodegenerative Diseases, High-Throughput Screening Assays. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 212 Literaturangaben. Gefördert von: HORIZON EUROPE European Research Council, European Commission Marie Sklodowska-Curie Actions.
Abstract (Originalsprache)
An increase in the aging population is accompanied by increased susceptibility to age-associated neurodegeneration, with currently no cure. Despite the diversity of symptoms and etiologies, neurodegenerative disorders share mechanistic commonalities and many pathophysiological features. These include disruptions in circadian rhythms that affect neuronal physiology. Systematic investigations in several animal models have advanced our understanding of the molecular processes that link circadian rhythms and neurodegenerative disease states. These models have also been used to screen and validate promising chronotherapeutic drug candidates that target the circadian clock to ameliorate neurodegeneration. With the emergence of robust and reliable methodologies to measure daily rhythms, the nematode model Caenorhabditis elegans has become a versatile tool for high throughput chronotherapeutic drug screening against neurodegenerative disorders. In this review, we discuss the unique features and advantages of C. elegans as an enabling platform for chronotherapeutic drug discovery, towards the development of innovative strategies for the treatment of human neurodegenerative conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion 70013 Crete, Greece; Department of Medicine, University of Verona, Verona 37134, Italy; Faculty of Pharmacy, Uni…
- Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion 70013 Crete, Greece; Division of Basic Sciences, School of Medicine, University of Crete, Heraklion 71003 Crete,…
- Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion 70013 Crete, Greece.
Förderung
- HORIZON EUROPE European Research Council
- European Commission Marie Sklodowska-Curie Actions
Zitieren
APA
Panda, M., Fakitsa, M., Markaki, M., & Tavernarakis, N. (2025). Caenorhabditis elegans as an emerging high throughput chronotherapeutic drug screening platform for human neurodegenerative disorders. Advanced Drug Delivery Reviews. https://doi.org/10.1016/j.addr.2025.115655
Vancouver
Panda M, Fakitsa M, Markaki M, Tavernarakis N. Caenorhabditis elegans as an emerging high throughput chronotherapeutic drug screening platform for human neurodegenerative disorders. Advanced Drug Delivery Reviews. 2025. doi:10.1016/j.addr.2025.115655
BibTeX
@article{Panda2025,
author = {Panda, Mrutyunjaya and Fakitsa, Maria and Markaki, Maria and Tavernarakis, Nektarios},
title = {Caenorhabditis elegans as an emerging high throughput chronotherapeutic drug screening platform for human neurodegenerative disorders},
journal = {Advanced Drug Delivery Reviews},
year = {2025},
doi = {10.1016/j.addr.2025.115655}
}
EUVIMED